SEC ownership of AIM ImmunoTech Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000946644.
- CIK
- 0000946644
- Symbol
- AIM on NYSE
- Location
- Ocala, FL
- Parsed ownership evidence
- 13D/G, 3/4/5, and 13F
- Lead holder
- Orca Capital AG
- 13D/G signal
- Orca Capital AG
- Latest evidence date
- 07 May 2026
Ownership snapshot
Top shareholders of AIM ImmunoTech Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Orca Capital AG |
13D/G
|
9.9%
|
$125,580
1,793,999 shares
|
$0 | 07 May 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$200,984
3,349,740 shares
|
$0 | 31 Dec 2024 |
| Todd Deutsch |
13D/G
|
2.7%
|
$102,966
1,716,100 shares
|
$0 | 19 Dec 2024 |
| William M. Mitchell |
3/4/5
Director
|
2.9%
|
$13,297
522,103 shares
|
— | 21 Apr 2025 |
| Ted D. Kellner |
3/4/5
Director
|
0.21%
|
$2,603
37,205 shares
|
— | 17 Jul 2025 |
| Stewart Appelrouth |
3/4/5
Director
|
—
class O/S missing
|
$76,968
388,729 shares
|
— | 31 Dec 2024 |
| Thomas K. Equels |
3/4/5
CEO & President, Director
|
—
mixed-class rows
|
$50,498
113,922 shares
mixed-class rows
|
— | 16 Mar 2026 |
| Peter W. Rodino III |
3/4/5
COO, Secretary, Gen. Counsel
|
—
class O/S missing
|
$34,953
401,762 shares
|
— | 04 Apr 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 29 May 2025.
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Current reporting-owner rows connected to AIM ImmunoTech Inc.. Open the relationship link for the CIK-to-CIK filing trail.
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Stewart Appelrouth | Director | $76,968 | Mixed | 31 Dec 2024 | ||
| Thomas K. Equels | CEO & President, Director | $50,498 | Mixed | 16 Mar 2026 | ||
| Peter W. Rodino III | COO, Secretary, Gen. Counsel | $34,953 | Filing P/S | 04 Apr 2025 | ||
| Nancy Bryan | Director | $33,858 | Mixed | 14 Mar 2025 | ||
| David I. Chemerow | Director | $22,468 | Mixed | 16 Mar 2026 | ||
| William M. Mitchell | Director | $13,297 | Mixed | 21 Apr 2025 | ||
| Ted D. Kellner | Director | $2,603 | Mixed | 17 Jul 2025 | ||
| Ellen M. Lintal | Former Chief Financial Officer | Mixed | 04 Apr 2022 | |||
| Robert Dickey IV | Chief Financial Officer | Mixed | 04 Apr 2022 |
Recent Insider Transactions by Companies or Individuals for AIM ImmunoTech Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Reported value | Reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Thomas K. Equels | AIM | Common stock | Conversion of derivative security | 64.2% | 25,000 | 63,922 | 12 Mar 2026 | Direct | ||
| Thomas K. Equels | AIM | Series G Convertible Preferred Stock | Conversion of derivative security | -100% | -25 | 0 | 12 Mar 2026 | Direct | ||
| David I. Chemerow | AIM | Common Stock | Conversion of derivative security | 726.5% | 25,000 | 28,441 | 12 Mar 2026 | Direct | ||
| David I. Chemerow | AIM | Series G Convertible Prefered Stock | Conversion of derivative security | -100% | -25 | 0 | 12 Mar 2026 | Direct | ||
| Thomas K. Equels | AIM | Class G Warrants | Other | 50,000 | 50,000 | 06 Mar 2026 | Direct | |||
| Thomas K. Equels | AIM | Series G Convertible Preferred Stock | Other | 25 | 25 | 06 Mar 2026 | Direct | |||
| David I. Chemerow | AIM | Class G Warrants | Other | 50,000 | 50,000 | 06 Mar 2026 | Direct | |||
| David I. Chemerow | AIM | Series G Convertible Preferred Stock | Other | 25 | 25 | 06 Mar 2026 | Direct | |||
| David I. Chemerow | AIM | Common Stock | Award | 436.8% | 2,800 | 3,441 | 05 Feb 2026 | The David I Chemerow 1992 Trust | ||
| Thomas K. Equels | AIMI | Common Stock | Purchase | 0.28% | 107 | 38,885 | 13 Jun 2025 | Direct | ||
| Thomas K. Equels | AIMI | Common Stock | Purchase | 0.27% | 103 | 38,675 | 12 Jun 2025 | Direct |